清髓性环境下非霍奇金淋巴瘤放射免疫治疗的剂量学方法
本文综述了非霍奇金淋巴瘤在清髓性预处理及造血干细胞移植前接受非标准化放射免疫治疗时所采用的内部剂量学方案。文章指出标准活度放射免疫治疗毒性可控且治疗前剂量学价值存在争议,而剂量递增方案则必须在治疗前评估放射性药物生物分布与剂量学,以避免高活度给药时关键器官剂量超限。
要点
- 标准活度放射免疫治疗毒性可控,治疗前剂量学的价值尚存争议
- 剂量递增方案需在治疗前评估生物分布与剂量学,以防止关键器官剂量超限
- 清髓性环境下放射免疫治疗旨在比较其与全身照射或大剂量化疗的疗效与毒性
核心结论
- 标准活度放射免疫治疗毒性可控,此情境下治疗前剂量学的价值可存争议
- 剂量递增临床方案要求在治疗注射前评估放射性药物生物分布与剂量学,因高活度给药时关键器官剂量限制可能被超出
研究设计与样本
- 本文为综述,旨在回顾和讨论非霍奇金淋巴瘤患者在清髓性预处理及造血干细胞移植前接受非标准化放射免疫治疗所采用的内部剂量学方案
- 放射免疫治疗是治疗非霍奇金淋巴瘤的安全且有效的手段,其中两种抗CD20单克隆抗体泽瓦林(90Y-替伊莫单抗替坦)与百克沙(131I-托西莫单抗)获FDA批准用于复发/难治性惰性或转化型非霍奇金淋巴瘤
主要发现
- 放射免疫治疗可能是非霍奇金淋巴瘤中最有效且毒性最低的抗癌手段
- 放射免疫治疗的临床应用仍存争议,在含利妥昔单抗优化方案后复发时,标准剂量放射免疫治疗疗效欠佳
- 临床试验基于以下假说:将放射免疫治疗纳入清髓性预处理,与清髓性全身照射和/或大剂量化疗方案相比可获得更优的疗效与毒性特征
关键数值与推荐
- 标准活度放射免疫治疗具有安全的毒性特征
- 剂量递增方案需在治疗前进行放射性药物生物分布与剂量学评估,因高活度给药时关键器官剂量限制可能被超出
临床怎么用
- 标准活度放射免疫治疗毒性可控,此情境下治疗前剂量学的价值可存争议
- 剂量递增临床方案要求在治疗注射前评估放射性药物生物分布与剂量学
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioimmunotherapy (RIT) is a safe and active treatment available for non-Hodgkin lymphomas (NHLs). In particular, two monoclonal antibodies raised against CD20, that is Zevalin (90Y-ibritumomab-tiuxetan) and Bexxar (131I-tositumomab) received FDA approval for the treatment of relapsing/refractory indolent or transformed NHLs. RIT is likely the most effective and least toxic anticancer agent in NHLs. However, its use in the clinical setting is still debated and, in case of relapse after optimized rituximab-containing regimens, the efficacy of RIT at standard dosage is suboptimal. Thus, clinical trials were based on the hypothesis that the inclusion of RIT in myeloablative conditioning would allow to obtain improved efficacy and toxicity profiles when compared to myeloablative total-body irradiation and/or high-dose chemotherapy regimens. Standard-activity RIT has a safe toxicity profile, and the utility of pretherapeutic dosimetry in this setting can be disputed. In contrast, dose-escalation clinical protocols require the assessment of radiopharmaceutical biodistribution and dosimetry before the therapeutic injection, as dose constrains for critical organs may be exceeded when RIT is administered at high activities. The aim of the present study was to review and discuss the internal dosimetry protocols that were adopted for non-standard RIT administration in the myeloablative setting before hematopoietic stem cell transplantation in patients with NHLs.
引用
- Cicone F, Sarnelli A, Guidi C, et al. Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting. Semin Nucl Med. 2022. PMID: 34996594. doi:10.1053/j.semnuclmed.2021.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。